GSK, RSV and Shingles
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in older adults (aged 50 years and older).
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
Good signs for co administration of GSK’s RSV and shingles vaccines
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial showed that co-administering Arexvy (RSV vaccine) and Shingrix (shingles vaccine) in adults 50+ produced a non-inferior immune response and was well tolerated.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV ... GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path ...
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
The American Journal of Managed Care4d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
Nasdaq2d
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...
Monthly Prescribing Reference3d
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...
CBC.ca3d
Canada approved multiple RSV shots to ward off infections this fall — here's how to get them
Here's what Canadians need to know: Older adults now have access to two approved vaccines, called Arexvy and Abrysvo.
Can I get flu, COVID and RSV vaccines together? What California health experts say about shots
The news comes as coronavirus cases rise in California and across the country. Along with the new COVID vaccines, ...